Sign In
Buy KOD
$33.87
+0.655 (+1.97%)
At Close: Jun 03, 2026
Bros. Advisors Lp Baker Acquires 2,608,696 Shares of Kodiak Sciences (NASDAQ:KOD) Stock
04:02am, Sunday, 21'st Dec 2025
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) Director Bros. Advisors Lp Baker acquired 2,608,696 shares of the firm's stock in a transaction dated Thursday, December 18th. The stock was bought
PALO ALTO, Calif. , Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing tran
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
10:55pm, Tuesday, 16'th Dec 2025
PALO ALTO, Calif. , Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing tran
Kodiak Sciences Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 15'th Dec 2025
PALO ALTO, Calif. , Dec. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing tran
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
08:41am, Friday, 14'th Nov 2025
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
04:05pm, Thursday, 13'th Nov 2025
PALO ALTO, Calif. , Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025.
Kodiak Sciences to Present at Upcoming Investor Conferences
05:48pm, Wednesday, 12'th Nov 2025
PALO ALTO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing tran
Meaningful vision gains are rapidly achieved as early as week 4 and showed continued improvement in best corrected visual acuity (BCVA) through week 20, with more than half of patients achieving impro
The Big 3: GOOGL, KOD, FTK
12:01pm, Friday, 31'st Oct 2025
Alphabet (GOOGL) spiked into its earnings this week, and @stockstotrade's Tim Bohen believes the Google parent company has much more room to run. He explains his bull case that rides on A.I.
Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain) A single dose of
Why Is Kodiak Sciences (KOD) Down 1.2% Since Last Earnings Report?
12:31pm, Friday, 12'th Sep 2025
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
PALO ALTO, Calif. , Sept. 2, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing tra
Harbour BioMed Reports 2025 Interim Results
10:40am, Wednesday, 27'th Aug 2025
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discove
Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock
06:54am, Wednesday, 27'th Aug 2025
On the latest edition of CNBC's “Mad Money Lightning Round,” Jim Cramer called Kodiak Sciences Inc. KOD is a “pure spec” stock.
Kodiak Sciences to Present at American Chemical Society Fall 2025
02:18pm, Tuesday, 19'th Aug 2025
PALO ALTO, Calif. , Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing tran
